Randomised phase II trial, 49 cisplatin-ineligible patients with metastatic urothelial carcinoma: objective response rate 69.6% with gemcitabine/carboplatin plus nivolumab vs 33.3% with gemcitabine/oxaliplatin plus nivolumab; median OS 24.74 vs 16.43 months (P=0.07).
RCTn = 49
Li et al. Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trial